DE69904302T2 - Farnesyltransferase-inhibitoren mit piperidinstruktur und verfahren zu ihrer herstellung - Google Patents

Farnesyltransferase-inhibitoren mit piperidinstruktur und verfahren zu ihrer herstellung

Info

Publication number
DE69904302T2
DE69904302T2 DE69904302T DE69904302T DE69904302T2 DE 69904302 T2 DE69904302 T2 DE 69904302T2 DE 69904302 T DE69904302 T DE 69904302T DE 69904302 T DE69904302 T DE 69904302T DE 69904302 T2 DE69904302 T2 DE 69904302T2
Authority
DE
Germany
Prior art keywords
formula
farnesyl transferase
piperid
production
transferase inhibitors
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
DE69904302T
Other languages
English (en)
Other versions
DE69904302D1 (de
Inventor
Seung Shin
Sung Koh
Il Lee
Ho Lee
Hyun Kim
Ho Chung
Hwa Kim
Hwan Kwak
Gu Ro
Ae Ahn
Saeng Choi
Hoon Oh
Mi Kim
Hwa Lee
Sung Kim
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
LG Corp
Original Assignee
LG Chemical Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from KR1019980002777A external-priority patent/KR100388789B1/ko
Priority claimed from KR1019980028340A external-priority patent/KR100388792B1/ko
Priority claimed from KR10-1998-0032150A external-priority patent/KR100388794B1/ko
Application filed by LG Chemical Co Ltd filed Critical LG Chemical Co Ltd
Application granted granted Critical
Publication of DE69904302D1 publication Critical patent/DE69904302D1/de
Publication of DE69904302T2 publication Critical patent/DE69904302T2/de
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Virology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Hydrogenated Pyridines (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)
DE69904302T 1998-02-02 1999-02-01 Farnesyltransferase-inhibitoren mit piperidinstruktur und verfahren zu ihrer herstellung Expired - Fee Related DE69904302T2 (de)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
KR1019980002777A KR100388789B1 (ko) 1998-02-02 1998-02-02 피롤구조를갖는파네실전이효소억제제및그의제조방법
KR19980002776 1998-02-02
KR1019980028340A KR100388792B1 (ko) 1998-02-02 1998-07-14 피페리딘구조를갖는파네실전이효소억제제및그의제조방법
KR10-1998-0032150A KR100388794B1 (ko) 1998-08-07 1998-08-07 피페리딘구조를갖는파네실전이효소억제제및그의제조방법
PCT/KR1999/000051 WO1999038862A1 (en) 1998-02-02 1999-02-01 Farnesyl transferase inhibitors having a piperidine structure and process for preparation thereof

Publications (2)

Publication Number Publication Date
DE69904302D1 DE69904302D1 (de) 2003-01-16
DE69904302T2 true DE69904302T2 (de) 2003-08-14

Family

ID=27483262

Family Applications (1)

Application Number Title Priority Date Filing Date
DE69904302T Expired - Fee Related DE69904302T2 (de) 1998-02-02 1999-02-01 Farnesyltransferase-inhibitoren mit piperidinstruktur und verfahren zu ihrer herstellung

Country Status (12)

Country Link
US (1) US6436960B1 (de)
EP (1) EP1058683B1 (de)
JP (1) JP3283032B2 (de)
CN (1) CN1158277C (de)
AT (1) ATE229017T1 (de)
AU (1) AU745855B2 (de)
BR (1) BR9908545A (de)
CA (1) CA2320233C (de)
DE (1) DE69904302T2 (de)
ES (1) ES2185307T3 (de)
PT (1) PT1058683E (de)
WO (1) WO1999038862A1 (de)

Families Citing this family (36)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR100388792B1 (ko) * 1998-02-02 2003-09-22 주식회사 엘지생명과학 피페리딘구조를갖는파네실전이효소억제제및그의제조방법
KR100388794B1 (ko) * 1998-08-07 2003-10-10 주식회사 엘지생명과학 피페리딘구조를갖는파네실전이효소억제제및그의제조방법
EP1169320B1 (de) * 1999-04-13 2004-09-22 LG Chem Investment, Ltd. Farnesyltransferase-inhibitoren die eine pyrrolstruktur haben und verfahren zu ihrer herstellung
KR20010063274A (ko) * 1999-12-22 2001-07-09 성재갑 〔1-｛〔1-（1,3-벤조디옥솔-5-일메틸-1ｈ-이미다졸-5-일〕메틸｝-4-(1-나프틸)-1ｈ-피롤-3-일〕（4-메틸-1-피페라지닐）메타논의 약학적 조성물
US7035932B1 (en) * 2000-10-27 2006-04-25 Eric Morgan Dowling Federated multiprotocol communication
US7132100B2 (en) 2002-06-14 2006-11-07 Medimmune, Inc. Stabilized liquid anti-RSV antibody formulations
US7425618B2 (en) 2002-06-14 2008-09-16 Medimmune, Inc. Stabilized anti-respiratory syncytial virus (RSV) antibody formulations
US8034831B2 (en) 2002-11-06 2011-10-11 Celgene Corporation Methods for the treatment and management of myeloproliferative diseases using 4-(amino)-2-(2,6-Dioxo(3-piperidyl)-isoindoline-1,3-dione in combination with other therapies
US7563810B2 (en) 2002-11-06 2009-07-21 Celgene Corporation Methods of using 3-(4-amino-1-oxo-1,3-dihydroisoindol-2-yl)-piperidine-2,6-dione for the treatment and management of myeloproliferative diseases
DK1572215T3 (da) 2002-12-20 2010-01-11 Glaxo Group Ltd Benzo[D]azepin-derivater til behandling af neurologiske lidelser
EP2316487B1 (de) 2003-04-11 2014-06-11 MedImmune, LLC Rekombinante IL-9 Antikörper und ihre Verwendung
ES2458636T3 (es) 2003-08-18 2014-05-06 Medimmune, Llc Humanización de anticuerpos
AU2004282189B2 (en) 2003-10-17 2011-11-17 Incyte Holdings Corporation Substituted cyclic hydroxamates as inhibitors of matrix metalloproteinases
EP1809326A4 (de) 2004-10-27 2009-11-04 Medimmune Inc Modulation von antikörperspezifität mittels anpassung der affinität zu verwandten antigenen
JP5153613B2 (ja) 2005-03-18 2013-02-27 メディミューン，エルエルシー 抗体のフレームワーク・シャッフル
JP2008546805A (ja) 2005-06-23 2008-12-25 メディミューン，エルエルシー 最適な凝集および断片化プロフィールを有する抗体製剤
EA021255B1 (ru) 2006-08-28 2015-05-29 Киова Хакко Кирин Ко., Лимитед Антагонистические моноклональные антитела человека, специфичные в отношении light человека
BRPI0809674A2 (pt) 2007-03-30 2014-10-07 Medimmune Llc Formulação aquosa estéril, estável, forma de dosagem unitária farmacêutica, recipiente selado, kit, método para prevenir, controlar, tratar ou melhorar uma doença ou distúrbio inflamatório, composição, processo para a preparação de uma composição, e, método para estabilizar um anticorpo 13h5
WO2012103165A2 (en) 2011-01-26 2012-08-02 Kolltan Pharmaceuticals, Inc. Anti-kit antibodies and uses thereof
GB201107985D0 (en) 2011-05-13 2011-06-29 Astrazeneca Ab Process
RU2681730C2 (ru) 2012-07-25 2019-03-12 Селлдекс Терапьютикс Инк. Антитела против kit и их применения
EP2906598A1 (de) 2012-10-09 2015-08-19 Igenica Biotherapeutics, Inc. Anti-c16orf54-antikörper und verfahren zur verwendung davon
NZ714765A (en) 2013-06-06 2021-12-24 Pf Medicament Anti-c10orf54 antibodies and uses thereof
KR102313341B1 (ko) 2013-08-26 2021-10-18 바이오엔테크 리서치 앤드 디벨롭먼트 인코포레이티드 시알릴-루이스 ａ에 대한 사람 항체 코드화 핵산
GB201403775D0 (en) 2014-03-04 2014-04-16 Kymab Ltd Antibodies, uses & methods
JP6626461B2 (ja) 2014-06-04 2019-12-25 バイオエヌテック リサーチ アンド デベロップメント， インコーポレイテッド ガングリオシドｇｄ２に対するヒトモノクローナル抗体
CA2970352A1 (en) 2014-12-11 2016-06-16 Pierre Fabre Medicament Anti-c10orf54 antibodies and uses thereof
FI3265123T3 (fi) 2015-03-03 2023-01-31 Vasta-aineita, käyttöjä & menetelmiä
WO2017096017A1 (en) 2015-12-02 2017-06-08 Stsciences, Inc. Antibodies specific to glycosylated btla (b- and t- lymphocyte attenuator)
CN114470194A (zh) 2015-12-02 2022-05-13 斯特库伯株式会社 与btn1a1免疫特异性结合的抗体和分子及其治疗用途
US11779604B2 (en) 2016-11-03 2023-10-10 Kymab Limited Antibodies, combinations comprising antibodies, biomarkers, uses and methods
KR20200015602A (ko) 2017-05-31 2020-02-12 주식회사 에스티큐브앤컴퍼니 Btn1a1에 면역특이적으로 결합하는 항체 및 분자 및 이의 치료적 용도
EP3630834A1 (de) 2017-05-31 2020-04-08 STCube & Co., Inc. Verfahren zur behandlung von krebs mit antikörpern und molekülen, die immunspezifisch an btn1a1 binden
CN110997724A (zh) 2017-06-06 2020-04-10 斯特库伯株式会社 使用结合btn1a1或btn1a1-配体的抗体和分子治疗癌症的方法
WO2019073069A1 (en) 2017-10-13 2019-04-18 Boehringer Ingelheim International Gmbh HUMAN ANTIBODIES AGAINST THOMSEN-NEW ANTIGEN (TN)
MA53160A (fr) 2018-07-20 2021-05-26 Pf Medicament Récepteur pour vista

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IE903957A1 (en) * 1989-11-06 1991-05-08 Sanofi Sa Aromatic amine compounds, their method of preparation and¹pharmaceutical compositions in which they are present
BR9306138A (pt) * 1992-03-25 1998-06-23 Pfizer Peptídeos antivirais
GB9312806D0 (en) * 1993-06-22 1993-08-04 Boots Co Plc Therapeutic agents
CA2250192A1 (en) * 1996-04-03 1997-10-09 Chrisopher J. Dinsmore Inhibitors of farnesyl-protein transferase
EP0891360A4 (de) * 1996-04-03 2002-05-15 Merck & Co Inc Inhibitoren der farnesyl-protein transferase
AU704792B2 (en) * 1996-04-03 1999-05-06 Merck & Co., Inc. Inhibitors of farnesyl-protein transferase
WO1997036587A1 (en) * 1996-04-03 1997-10-09 Merck & Co., Inc. A method of treating cancer
AU715202B2 (en) * 1996-04-03 2000-01-20 Merck & Co., Inc. Inhibitors of farnesyl-protein transferase
RU2179975C1 (ru) * 1997-11-28 2002-02-27 Эл Джи Кемикал Лтд. Производные имидазола, обладающие ингибирующей активностью в отношении фарнезилтрансферазы, способ их получения, промежуточные соединения, фармацевтическая композиция

Also Published As

Publication number Publication date
JP3283032B2 (ja) 2002-05-20
CN1289331A (zh) 2001-03-28
AU745855B2 (en) 2002-04-11
EP1058683A1 (de) 2000-12-13
ES2185307T3 (es) 2003-04-16
CA2320233A1 (en) 1999-08-05
EP1058683B1 (de) 2002-12-04
JP2002501918A (ja) 2002-01-22
PT1058683E (pt) 2003-04-30
WO1999038862A1 (en) 1999-08-05
US6436960B1 (en) 2002-08-20
CA2320233C (en) 2004-07-27
ATE229017T1 (de) 2002-12-15
BR9908545A (pt) 2001-10-02
DE69904302D1 (de) 2003-01-16
CN1158277C (zh) 2004-07-21
AU2188699A (en) 1999-08-16

Similar Documents

Publication Publication Date Title
DE69904302D1 (de) Farnesyltransferase-inhibitoren mit piperidinstruktur und verfahren zu ihrer herstellung
HUP0400636A2 (hu) Azetidinszármazékokat tartalmazó gyógyszerkészítmények, új azetidinszármazékok és előállításuk
NO990551L (no) Piperidin- og piperazinderivater, og deres anvendelse som muskarine antagonister
NO20052683L (no) Nye pyridopyrimidinonforbindelser, fremgangsmate for deres fremstilling og farmasoytiske sammensetninger inneholdende dem
HUP9702345A2 (hu) 3-Hidroxi-piridin-2-karbonsav-amid-észter-származékok, eljárás előállításukra, e vegyületeket tartalmazó gyógyszerkészítmények és alkalmazásuk
HUP9802762A2 (hu) Difenil-metilén-piperidin-származékok, e vegyületeket tartalmazó gyógyászati készítmények, eljárás előállításukra és alkalmazásuk
ATE302778T1 (de) N-substituierte 4-aminopteridine, verfahren zu ihrer herstellung und ihre verwendung als arzneimittel
ATE146473T1 (de) Pyrazolopyridinverbindungen und verfahren zu ihrer herstellung
NO20040881L (no) Orale antidiabetes midler.
NO20002099L (no) 6,11-bro-erytromycinderivater
DK1233953T3 (da) Nye benzoethiadiazinderivater, fremgangsmåde til fremstilling heraf og farmaceutiske sammensætninger indeholdende samme
ATE141606T1 (de) Cephemverbindungen und verfahren zu ihrer herstellung
NO20023001L (no) Substituerte piperazinderivater som MTP inhibitorer
ATE310010T1 (de) 6-0-substitutierte eryththromycin-verbindungen und verfahrenen zu ihrer herstellung
NO20045132L (no) Benzo(c)kinolizinderivater, deres fremstilling og anvendelse som 5alfa- reduktaseinhibitorer
ATE214051T1 (de) Substituierte tetrahydropyridinderivate, verfahren zu ihrer herstellung und diese enthaltende arzneimittel
ATE165822T1 (de) Chinolin-4-carbonylguanidin-derivate, verfahren zu ihrer herstellung und diese enthaltende pharmazeutische zusammensetzungen
EA200000389A3 (ru) Новые замещенные пиридины или пиперидины, способ их получения и содержащие их фармацевтические композиции
EP1123923A4 (de) Dihydropyridin-derivate und drogen gemenge, die diese enthalten
DE3480839D1 (de) Benzimidazol-derivat, verfahren zu seiner herstellung und pharmazeutische zusammensetzung.
NO975402L (no) Nye benzopyran forbindelser, fremgangsmÕte ved fremstilling av dem og farmas÷ytiske sammensetninger som inneholder dem
NZ543068A (en) Substituted 4-(alkyl-amide)-piperidine derivatives, processes for their preparation, and pharmaceutical compositions containing them
DE69927997D1 (de) Neuartige pyrimidin-derivate und verfahren zu ihrer herstellung
HUP0303676A2 (hu) Helyettesített 4-fenil-1-(1-fenil-ciklohexil)-1,2,3,6-tetrahidropiridinek, eljárás az előállításukra és ezeket tartalmazó gyógyszerkészítmények
ATE50248T1 (de) Ein imidazolidintrion-derivat oder ein seiner pharmazeutisch akzeptierbaren salze enthaltende pharmazeutische zusammenstellung.

Legal Events

Date Code Title Description
8339 Ceased/non-payment of the annual fee